

# Ontario Public Drug Programs

## Drug Submission Status

---

**Generic Name:** ruxolitinib

**Brand Name:** Jakavi

**Strength:** 5mg, 15mg and 20mg tablet

**Manufacturer:** Novartis Pharmaceuticals Canada Inc.

**Indication:** The treatment of splenomegaly and/or its associated symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis

**Rapid Review:** Not requested

Submission Type:	Date Submission Received:	Date Submission Deemed Complete:	Review Status:	Funding Decision:
First Review (Initial Submission)	20/08/2012	30/10/2012	EO decision rendered	Funding considered through the Exceptional Access Program (EAP)

### Rapid Review:

Details of the Rapid Review process can be found at:

[http://www.health.gov.on.ca/en/pro/programs/drugs/drug\\_submissions/rapid\\_review\\_process.aspx](http://www.health.gov.on.ca/en/pro/programs/drugs/drug_submissions/rapid_review_process.aspx)

### Review Status:

- Screening – Ministry is screening the manufacturer’s submission to ensure all regulatory and policy requirements have been met in order to proceed with the drug review.
- Submission incomplete – Manufacturer did not meet the necessary requirements to allow review to proceed.
- Submission complete & under review – Manufacturer met all requirements to proceed with the drug review, and evaluation of the drug submission is underway.
- Committee to Evaluate Drugs (CED) review completed, manufacturer requesting reconsideration – A recommendation was made by the CED, however the manufacturer has submitted or will be submitting additional information.
- Committee to Evaluate Drugs (CED) review completed – A recommendation was made by the CED.

- Executive Officer (EO) decision rendered.

## Funding Status:

The Committee to Evaluate Drugs (CED) recommendation and the Executive Officer (EO) decision, if available, can be found at:

[http://www.health.gov.on.ca/en/pro/programs/drugs/ced\\_rec\\_table.aspx](http://www.health.gov.on.ca/en/pro/programs/drugs/ced_rec_table.aspx)

Updated: September 19, 2013